Loughborough University
Leicestershire, UK
LE11 3TU
+44 (0)1509 263171
Loughborough University

Loughborough University Institutional Repository

Please use this identifier to cite or link to this item: https://dspace.lboro.ac.uk/2134/4264

Title: Cell Culture Automation and Quality Engineering: A Necessary Partnership to Develop Optimized Manufacturing Processes for Cell-Based Therapies
Authors: Thomas, Robert James
Chandra, Amit
Hourd, Paul C.
Williams, David J.
Keywords: Cell therapy
Manufacture
Process engineering
Issue Date: 2008
Publisher: © Elsevier
Citation: THOMAS, R.J. ... et al, 2008. Cell Culture Automation and Quality Engineering: A Necessary Partnership to Develop Optimized Manufacturing Processes for Cell-Based Therapies. Journal of The Association for Laboratory Automation, 13 (3), pp. 152 - 158
Abstract: The translation of experimental cell-based therapies to volume produced commercially successful clinical products that satisfy the regulator requires the development of automated manufacturing processes to achieve capable and scaleable processes that are both economic and able to meet the unpredictable demands of the market place. The Healthcare Engineering group at Loughborough has conducted novel demonstrators of the transfer of manual human cell culture processes to the CompacT SelecT (The Automation Partnership) automated cell culture platform, including an osteoblast cell line, embryonic carcinoma cell line, primary bone marrow-derived mesenchymal stem cells, primary umbilical cord-derived progenitor cells, and human embryonic stem cells. The work aims to develop and optimize automated cell culture processes for manufacturing cell-based therapies in a quality system and current good manufacturing practice (cGMP) compliant manner and is underpinned by the application of a sixsigma inspired quality engineering approach. In this technical brief, we outline the need for automated cell culture systems and automated process engineering for the manufacture of cell populations for therapeutic applications. We review the transfer of a manual cell culture process to an automated process and the subsequent methodology for process improvement using examples from our laboratory of the application of these principles to an important regenerative medicine cell type, the human mesenchymal stem cell. We believe that systematic process improvement methodologies combined with the process stability provided by automation are essential to engineer optimized cGMP compliant manufacturing processes that will be required to realize the promise of cell-based therapies
Description: This article is Restricted Access. It was published in the Journal of The Association for Laboratory Automation [© Elsevier]. The definitive version is available at: http://www.journals.elsevierhealth.com/periodicals/xyjala
Version: Restricted access
DOI: 10.1016/j.jala.2007.12.003
URI: https://dspace.lboro.ac.uk/2134/4264
ISSN: 1535-5535
Appears in Collections:Closed Access (Mechanical and Manufacturing Engineering)

Files associated with this item:

File Description SizeFormat
JALA article published.pdf752.83 kBAdobe PDFView/Open

 

SFX Query

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.